The natural history of progressive fibrosing interstitial lung diseases
Kevin K. Brown(Boston Children's Hospital), Athol U. Wells(Royal Brompton Hospital), Antje Prasse(University Medical Center Freiburg), Rainer-Georg Goeldner(Boehringer Ingelheim (Germany)), Rozsa Schlenker‐Herceg(Royal Brompton & Harefield NHS Foundation Trust), Victor J. Thannickal(Pulmonary and Allergy Associates), Fernando J. Martínez(University of Michigan–Ann Arbor), Kay Tetzlaff(Boehringer Ingelheim (Taiwan)), Vincent Cottin(Université Claude Bernard Lyon 1), Emmanuelle Clerisme-Beaty(Royal Brompton & Harefield NHS Foundation Trust), Simon Walsh(Royal Brompton & Harefield NHS Foundation Trust)
Cited by 288
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k